Literature DB >> 16317092

Impaired class switch recombination (CSR) in Waldenstrom macroglobulinemia (WM) despite apparently normal CSR machinery.

Jitra Kriangkum1, Brian J Taylor, Erin Strachan, Michael J Mant, Tony Reiman, Andrew R Belch, Linda M Pilarski.   

Abstract

Analysis of clonotypic isotype class switching (CSR) in Waldenström macroglobulinemia (WM) and IgM monoclonal gammopathy of undetermined significance (MGUS) reveals a normal initial phase of B-cell activation as determined by constitutive and inducible expression of activation-induced cytidine deaminase (AID). Switch mu (Smu) analysis shows that large deletions are not common in WM or IgM MGUS. In CD40L/IL-4-stimulated WM cultures from 2 patients, we observed clonotypic IgG exhibiting intraclonal homogeneity associated with multiple hybrid Smu/Sgamma junctions. This suggests CSR had occurred within WM cells. Nevertheless, the estimated IgG/IgM-cell frequency was relatively low (1/1600 cells). Thus, for the majority of WM B cells, CSR does not occur even when stimulated in vitro, suggesting that the WM cell is constitutively unable to or being prevented from carrying out CSR. In contrast to WM, the majority of IgM MGUS clones exhibit intraclonal heterogeneity of IgH VDJ. Furthermore, most IgM MGUS accumulate more mutations in the upstream Smu region than do WM, making them unlikely WM progenitors. These observations suggest that switch sequence analysis may identify the subset of patients with IgM MGUS who are at risk of progression to WM.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16317092     DOI: 10.1182/blood-2005-09-3613

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma.

Authors:  Wee J Chng; Roelandt F Schop; Tammy Price-Troska; Irene Ghobrial; Neil Kay; Diane F Jelinek; Morie A Gertz; Angela Dispenzieri; Martha Lacy; Robert A Kyle; Philip R Greipp; Renee C Tschumper; Rafael Fonseca; Peter Leif Bergsagel
Journal:  Blood       Date:  2006-06-27       Impact factor: 22.113

2.  Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia.

Authors:  Mark Bustoros; Romanos Sklavenitis-Pistofidis; Prashant Kapoor; Chia-Jen Liu; Efstathios Kastritis; Saurabh Zanwar; Geoffrey Fell; Jithma P Abeykoon; Kalvis Hornburg; Carl Jannes Neuse; Catherine R Marinac; David Liu; Jenny Soiffer; Maria Gavriatopoulou; Cody Boehner; Joseph M Cappuccio; Henry Dumke; Kaitlen Reyes; Robert J Soiffer; Robert A Kyle; Steven P Treon; Jorge J Castillo; Meletios A Dimopoulos; Stephen M Ansell; Lorenzo Trippa; Irene M Ghobrial
Journal:  J Clin Oncol       Date:  2019-04-16       Impact factor: 44.544

3.  Landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance to LPL/WM.

Authors:  Jun Wang; Yuting Yan; Wenjie Xiong; Ge Song; Yi Wang; Jiawei Zhao; Yujiao Jia; Chengwen Li; Zhen Yu; Ying Yu; Jiawen Chen; Yang Jiao; Tingyu Wang; Rui Lyu; Qinghua Li; Yueshen Ma; Wei Liu; Dehui Zou; Gang An; Qi Sun; Huijun Wang; Zhijian Xiao; Jianxiang Wang; Lugui Qiu; Shuhua Yi
Journal:  Blood Adv       Date:  2022-07-12

4.  Clinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential.

Authors:  Philip Savage
Journal:  BMC Cancer       Date:  2015-01-21       Impact factor: 4.430

Review 5.  Factors regulating immunoglobulin production by normal and disease-associated plasma cells.

Authors:  David A Jackson; Sherine F Elsawa
Journal:  Biomolecules       Date:  2015-01-21

6.  B-Cell-Specific Myd88 L252P Expression Causes a Premalignant Gammopathy Resembling IgM MGUS.

Authors:  Kristin Schmidt; Ulrike Sack; Robin Graf; Wiebke Winkler; Oliver Popp; Philipp Mertins; Thomas Sommermann; Christine Kocks; Klaus Rajewsky
Journal:  Front Immunol       Date:  2020-12-01       Impact factor: 7.561

7.  Waldenström's macroglobulinemia harbors a unique proteome where Ku70 is severely underexpressed as compared with other B-lymphoproliferative disorders.

Authors:  A Perrot; C Pionneau; N Azar; C Baillou; F M Lemoine; V Leblond; H Merle-Béral; M-C Béné; R Herbrecht; S Bahram; L Vallat
Journal:  Blood Cancer J       Date:  2012-09-07       Impact factor: 11.037

Review 8.  Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models.

Authors:  Siegfried Janz
Journal:  ISRN Hematol       Date:  2013-09-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.